首页> 美国卫生研究院文献>Breast Cancer Research : BCR >High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy
【2h】

High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy

机译:乳腺癌研究和临床管理中的高通量基因组技术。血浆蛋白质组学在早期发现和治疗中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Protein-based breast cancer biomarkers are a promising resource for breast cancer detection at the earliest and most treatable stages of the disease. Plasma is well suited to proteomic-based methods of biomarker discovery because it is easily obtained, is routinely used in the diagnosis of many diseases, and has a rich proteome. However, due to the vast dynamic range in protein concentration and the often uncertain tissue and cellular origin of plasma proteins, proteomic analysis of plasma requires special consideration compared with tissue and cultured cells. This review briefly touches on the search for plasma-based protein biomarkers for the early detection and treatment of breast cancer.
机译:基于蛋白质的乳腺癌生物标记物是在疾病的最早,最可治疗的阶段进行乳腺癌检测的有前途的资源。血浆非常容易获得,是基于蛋白质组学的生物标记物发现方法,因为它易于获得,通常用于诊断许多疾病,并且蛋白质组丰富。然而,由于蛋白质浓度的巨大动态范围以及血浆蛋白质的通常不确定的组织和细胞起源,与组织和培养细胞相比,血浆蛋白质组学分析需要特别考虑。这篇综述简要地探讨了基于血浆的蛋白质生物标记物的发现,以用于乳腺癌的早期检测和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号